PhaseBio Pharmaceuticals (PHAS) Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PHAS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PHAS, but not buy additional shares or sell existing shares.
View PHAS analyst ratings or view top-rated stocks.

5 analysts have issued 1-year price objectives for PhaseBio Pharmaceuticals' shares. Their PHAS share price forecasts range from $1.00 to $8.00. On average, they anticipate the company's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 749,900.0% from the stock's current price.
View analysts price targets for PHAS or view top-rated stocks among Wall Street analysts.

PhaseBio Pharmaceuticals' stock was trading at $0.0301 at the start of the year. Since then, PHAS shares have decreased by 98.0% and is now trading at $0.0006.
View the best growth stocks for 2023 here.

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by $0.07. The company had revenue of $0.34 million for the quarter, compared to analyst estimates of $2.67 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT) and Agile Therapeutics (AGRX).

(PHAS) raised $66 million in an IPO on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

Shares of PHAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PHAS stock can currently be purchased for approximately $0.00.

PhaseBio Pharmaceuticals (NASDAQ:PHAS) has a market capitalization of $29,914.80 and generates $818,000.00 in revenue each year. The company earns $-131,070,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis.

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The official website for the company is www.phasebio.com. The company can be reached via phone at (610) 981-6500 or via email at pmobley@nobleromans.com.